Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukemia in chronic phase

被引：0
|
作者：
Quintas-Cardama, A.
Kantarjian, H.
OBrien, S.
Jones, D.
Borthakur, G.
Nicaise, C.
Cortes, J.
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0360
引用
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [1] Use of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP)
    Atallah, E. L.
    Kantarjian, H.
    O'Brien, S.
    Jones, D.
    Borthakur, G.
    Nicaise, C.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Dasatinib (SPRYCEL®) in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP).
    Cortes, Jorge
    O'Brien, S.
    Jones, D.
    Borthakur, G.
    Giles, F.
    Nicaise, C.
    Kantarjian, H. M.
    BLOOD, 2006, 108 (11) : 613A - 613A
  • [3] Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Borthakur, Gautam
    Jones, Dan
    Ravandi, Farhad
    Koller, Charles
    Mesina, Ofelia
    Ferrajoli, Alessandra
    Shan, Jianqin
    Kantarjian, Hagop
    BLOOD, 2008, 112 (11) : 74 - 74
  • [4] EFFICACY OF DASATINIB IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED CHRONIC MYELOGENOUS LEUKEMIA (CML) IN EARLY CHRONIC PHASE (CML-CP)
    Cortes, J.
    Borthakur, G.
    Jones, D. M.
    O'Brien, S.
    Koller, C. A.
    Nicaise, C.
    Garcia-Manero, G.
    Ferrajoli, A.
    Kantarjian, H. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 349 - 349
  • [5] Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Jones, Dan
    Koller, Charles
    Borthakur, Gautam
    Nicaise, Claude
    Henderson, Laverne
    Ferrajoli, Alessandra
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 17A - 17A
  • [6] Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)
    Borthakur, G.
    Kantarjian, H. M.
    O'Brien, S. M.
    Jones, D.
    Koller, C.
    Nicaise, C.
    Garcia-Manero, G.
    Ferrajoli, A.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP)
    Cortes, Jorge
    Borthakur, Gautam
    O'Brien, Susan
    Jones, Dan
    Jabbour, Elias
    Ravandi, Farhad
    Koller, Charles
    Walker, Brenda
    Shan, Jenny
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 143 - 143
  • [8] Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial
    Millot, Frederic
    Baruchel, Andre
    Guilhot, Joelle
    Petit, Arnaud
    Leblanc, Thierry
    Bertrand, Yves
    Mazingue, Francoise
    Lutz, Patrick
    Verite, Cecile
    Berthou, Christian
    Galambrun, Claire
    Bernard, Frederic
    Yacouben, Karima
    Bordigoni, Pierre
    Edan, Christine
    Reguerre, Yves
    Couillault, Gerard
    Mechinaud, Francoise
    Cayuela, Jean-Michel
    Guilhot, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (20) : 2827 - 2832
  • [9] Dasatinib in chronic myelogenous leukemia
    Chu, Sung-Chao
    Tang, Jih-Luh
    Li, Chi-Cheng
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (10): : 1062 - 1063
  • [10] Dasatinib in chronic myelogenous leukemia - Reply
    Sawyers, Charles L.
    Talpaz, Moshe
    Bleickardt, Eric
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (10): : 1063 - 1064
12345